← All trials
NCT06359353
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 8, 2019
- Primary completion
- Feb 10, 2022
- Completion date
- Dec 19, 2023
- First posted
- Apr 11, 2024
- Last posted
- Apr 11, 2024
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Seoul National UniversityLead sponsor
- Seoul National UniversityOfficial
- JW PharmaceuticalCollaborator
- Seoul National UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.